中国医学创新Issue(36)：43-44,45,3.DOI:10.3969/j.issn.1674-4985.2013.36.019
卡培他滨联合曲妥珠单抗治疗Her-2阳性老年转移性乳腺癌的疗效观察
Clinical Efficacy Evaluation of Capecitabine Plus Transtuzumab in Older Patients with Her-2 Positive Metastatic Breast Cancer
张月秋 1张海青 1孙宝臣 1王坤 1杨晓洲1
作者信息
- 1. 辽宁省大连市中心医院 辽宁 大连 116033
- 折叠
摘要
Abstract
Objective:To evaluate the clinical efficacy and safety of capecitabine plus transtuzumab in older patients with Her-2 positive metastatic breast cancer(MBC). Method:Thirty two older patients(≥65 years)with Her-2 over expressing recurrent or metastatic breast cancer(MBC) confirmed by pathology enrolled into the study. The patients received capecitabine 1250 mg/m2 twice daily,1-14 days,combined with intravenous transtuzumab 8 mg/kg body weight on day 1(loading dose),followed by 6 mg/kg every 3 weeks,and were evaluated efficacy every 2 cycles. Result:Complete remission( CR)was 2 cases(6.2%),PR was 10 cases(31.3%),11 cases had stable disease(SD)lasting at least 6 months(34.4%)and 9 cases(28.1%)got progressive disease(PD). The total effective rate was 37.5%(12/32),the clinical benefit response rate(CR+PR+SD)was 71.9%(23/32). The median time to progression(TTP)was 8.5 months. The safety profile of the combination was favorable. The main side effects were hand-foot syndrome,diarrhea and stomatitis which were all tolerable. Only one patient suffered from symptomatic chronic heart failure,which improved after discontinuation of transtuzumab. There were no treatment-related deaths. Conclusion:The combination therapy of capecitabine plus transtuzumab is effective and tolerable for older patients with Her-2 positive MBC,it is a safe and active palliative treatment option.关键词
卡培他滨/曲妥珠单抗/Her-2阳性/老年转移性乳腺癌Key words
Capecitabine/Transtuzumab/Her-2positive/Elder MBC引用本文复制引用
张月秋,张海青,孙宝臣,王坤,杨晓洲..卡培他滨联合曲妥珠单抗治疗Her-2阳性老年转移性乳腺癌的疗效观察[J].中国医学创新,2013,(36):43-44,45,3.
